Literature DB >> 15943974

Transglutaminase 2 in the balance of cell death and survival.

László Fésüs1, Zsuzsa Szondy.   

Abstract

Transglutaminase 2 (TG2), a multifunctional enzyme with Ca(2+)-dependent protein crosslinking activity and GTP-dependent G protein functions, is often upregulated in cells undergoing apoptosis. In cultured cells TG2 may exert both pro- and anti-apoptotic effects depending upon the type of cell, the kind of death stimuli, the intracellular localization of the enzyme and the type of its activities switched on. The majority of data support the notion that transamidation by TG2 can both facilitate and inhibit apoptosis, while the GTP-bound form of the enzyme generally protects cells against death. In vivo studies confirm the Janus face of TG2 in the initiation of the apoptotic program. In addition, they reveal a further role: the prevention of inflammation, tissue injury and autoimmunity once the apoptosis has already been initiated. This function of TG2 is partially achieved by being expressed and activated also in macrophages digesting apoptotic cells and mediating a crosstalk between dying and phagocytic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943974     DOI: 10.1016/j.febslet.2005.03.063

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  57 in total

1.  Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.

Authors:  Sung-Yup Cho; Kyungho Choi; Ju-Hong Jeon; Chai-Wan Kim; Dong-Myung Shin; Jong Bouk Lee; Sang Eun Lee; Choung-Soo Kim; Jeong-Soo Park; Eui Man Jeong; Gi-Yong Jang; Kye-Yong Song; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

2.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Transglutaminase 2 inhibits apoptosis induced by calcium- overload through down-regulation of Bax.

Authors:  Sung-Yup Cho; Jin-Haeng Lee; Han-Dong Bae; Eui Man Jeong; Gi-Yong Jang; Chai-Wan Kim; Dong-Myung Shin; Ju-Hong Jeon; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-09-30       Impact factor: 8.718

Review 4.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

5.  Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death.

Authors:  Sung-Yup Cho; Eui Man Jeong; Jin-Haeng Lee; Hyo-Jun Kim; Jisun Lim; Chai-Wan Kim; Dong-Myung Shin; Ju-Hong Jeon; Kyungho Choi; In-Gyu Kim
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

6.  Transglutaminase 2 expression is enhanced synergistically by interferon-γ and tumour necrosis factor-α in human small intestine.

Authors:  M Bayardo; F Punzi; C Bondar; N Chopita; F Chirdo
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

7.  Cryopreservation effects on Wharton's Jelly Stem Cells proteome.

Authors:  F Di Giuseppe; L Pierdomenico; E Eleuterio; M Sulpizio; P Lanuti; A Riviello; G Bologna; M Gesi; C Di Ilio; S Miscia; M Marchisio; S Angelucci
Journal:  Stem Cell Rev Rep       Date:  2014-06       Impact factor: 5.739

Review 8.  Role of transglutaminase 2 in celiac disease pathogenesis.

Authors:  Cornelius Klöck; Thomas R Diraimondo; Chaitan Khosla
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

9.  Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems.

Authors:  Michael Zangani; Harald Carlsen; Anders Kielland; Audun Os; Harald Hauglin; Rune Blomhoff; Ludvig A Munthe; Bjarne Bogen
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.